Trevicta (Paliperidone Palmitate)

Trevicta (paliperidone palmitate) is an extended-release injectable antipsychotic medication used for schizophrenia maintenance. This long-acting formulation provides steady symptom control with monthly dosing. Trevicta helps manage psychotic symptoms while reducing daily pill burden for patients and caregivers.

Trevicta is used to treat schizophrenia in adults, providing continuous symptom management between doses. This injectable formulation is designed for maintenance therapy, helping prevent relapse by maintaining stable medication levels. It's particularly useful for patients who struggle with daily oral medication adherence or require long-term symptom stabilization.

Patients using Trevicta typically experience gradual improvement in psychotic symptoms over several weeks. Common effects include reduced hallucinations and delusions, improved thinking clarity, and enhanced daily functioning. The medication works systemically to help restore chemical balance in the brain over time.

Trevicta requires administration by a healthcare professional due to its intramuscular route. Patients should discuss their full medical history with their doctor, especially regarding heart conditions or seizures. Regular follow-up appointments are important to monitor treatment progress and adjust care as needed.

Trevicta may interact with other medications affecting the central nervous system, including sedatives and certain antidepressants. Alcohol should be avoided as it may increase drowsiness. Patients should inform their doctor about all prescription and over-the-counter medications they're taking before starting Trevicta.